Doxorubicin (generic), Adriamycin, Doxil News

Thermoresponsive polymer-coated magnetic nanoparticles loaded with anti-cancer drugs are of considerable interest for novel multi-modal cancer therapies.

Critical Outcome Technologies Inc. , announced positive results today from combination agent animal experiments carried out at a prominent American cancer research facility.

Critical Outcome Technologies reports positive results with intravenous COTI-2 plus Doxil in animal model of human ovarian cancer Published in M2Europharma on Thursday, 02 July 2009 at 19:07 GMT 2 July 2009 - Canadian biotechnology company Critical Outcome Technologies Inc reported today encouraging results with intravenous COTI-2 in combination ...

A pH responsive film that releases drugs to kill cancer cells could find applications from implant coatings to drug delivery systems, say scientists in the US and Korea.

The Phase II clinical study, called "PRECEDENT," is designed to evaluate the safety and efficacy of EC145, a drug currently being studied in the treatment for women with ovarian cancer who develop a resistance to standard platinum-based chemotherapy.

Abstract One half of patients newly diagnosed with lymphoma are older than 60 years and a significant proportion of them older than 80 years.

Contact Description: Exposure to particulate matter air pollution results in airways hyperresponsiveness , however it also results in adverse cardiovascular effects, particularly in individuals with underlying cardiovascular disease.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration .

In what researchers are calling a breakthrough, patients with thyroid cancer that is resistant to radioactive iodine therapy were found to respond well to sorafenib, a University of Pennsylvania School of Medicine researcher reported today at the annual meeting of the American Society of Clinical Oncology .

Therapeutics, Inc. announced today that at the poster and discussion session of the Lymphoma and Plasma Cell Disorders Section at the 2009 American Society of Clinical Oncology Annual Meeting, new subgroup analysis data were reviewed from the phase III EXTEND clinical trial of pixantrone demonstrating the effectiveness of pixantrone as therapy in ...

Panel Discussant Focuses on Longer Duration of Remission among Patients Achieving a Complete Remission with Pixantrone than Complete Remissions Achieved with Standard Chemotherapy ORLANDO , June 2 /PRNewswire-FirstCall/ -- Therapeutics, Inc.

In Clinical Trials VELCADE for Injection as a Foundation of Therapy Continues to Deliver Significant Response Rates in Previously Untreated Multiple Myeloma Patients ORLANDO, Fla.-- --May 31, 2009 - Millennium: The Takeda Oncology Company today reported the presentation of results from two clinical trials of VELCADE based combinations for the ...

ZIOPHARM Oncology, Inc. announced today that it presented final data from a Phase I study of palifosfamide in combination with doxorubicin at the 45th Annual American Society of Clinical Oncology meeting held in Orlando, FL, May 29th to June 2nd.

Millennium: The Takeda Oncology Company today reported data from two clinical trials evaluating VELCADE based combinations for patients with non-Hodgkin's lymphoma .

Effects of MYC Protein and CIP2A in Gastric Cancer The presence of the protein CIP2A in tumors is associated with early mortality for gastric cancer patients, according to a new study by Ari Ristimaki, M.D., Ph.D., of the Genome-Scale Biology Research program at the University of Helsinki and colleagues.

An 84-year-old man presented with an isolated sensation of a lump in the back of his throat and difficulty swallowing that had developed over several months.

The ensuing accumulation of nuclear NRF-1 protein leads to gene activation for mitochondrial biogenesis, which opposes apoptosis and necrosis caused by the cardio-toxic anthracycline chemotherapeutic agent, doxorubicin.

ATLANTA, May 19, 2009 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. released updated safety data today from its pixantrone phase III 301 EXTEND trial demonstrating the effectiveness of pixantrone in patients with relapsed/refractory aggressive non-Hodgkin's lymphoma for whom anthracycline-related drugs are typically not to be used due to the ...

We determined the association between CD20 expression and clinical outcome in patients with diffuse large B-cell lymphoma .

Doxorubicin is an effective breast cancer drug but is hampered by a severe, dose-dependent toxicity.